-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
-
Peter Hammerman, MD, PhD
Posted: February 2017 Peter Hammerman has been appointed Global Head, Oncology Translational Research at Novartis Institutes for BioMedical Research (NIBR). Previous to this appointment, Dr. Hammerman was a Medical Oncologist and Physician Scientist at Dana-Farber Cancer Institute and Assistant Professor, Medicine, Harvard Medical School, Boston, US.
-
FDA Corner – Interview with Amy Mckee, MD
Posted: February 2017 BY Erik J. Maclaren, PhD Breakthrough Therapy Designation and Mechanisms of Expedited Review The U.S. Food and Drug Administration (FDA) is responsible for reviewing the evidence of safety and efficacy for all new drugs before they can be made available to patients. Increasing the efficiency and speed of the approval process for…
-
PD-L1 Blueprint Project
Posted: February 2017 By Fred R. Hirsch, MD, PhD In the new era of immunotherapy in thoracic cancer, evaluating PD-L1 status remains a clinical challenge. In recognition of the potential confusion generated by having multiple predictive assays related to the same “family” of drugs, a workshop led by the U.S. Food and Drug Administration (FDA),…
-
Welcome to Year Two of the IASLC Lung Cancer News
Posted: February 2017 From the Editor / Corey J. Langer, MD, FACP A new year has dawned, and with it both excitement and uncertainty in the field of thoracic oncology. In the past half-decade, we have witnessed a “tsunami” of progress in the management of advanced disease, especially non-small cell lung cancer (NSCLC). The burgeoning…
-
Drug Development in the 21st Century
Posted: February 2017 By Lori Alexander, MTPW, ELS, MWC Drug development has become a biomarker- driven process, necessitating new approaches and clinical trial designs. Speakers addressed these issues in the WCLC session “Anticancer Drug Development in the 21st Century.” Former IASLC President Tony Mok, MD, of Chinese University of Hong Kong, explained that the two…
-
Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A New Paradigm Post-IASLC WCLC 2016
Posted: February 2017 By Melody Watson The first plenary session on the last day of IASLC WCLC 2016 covered one of the most exciting areas in NSCLC research today: immunotherapy. The first speaker, Julie R. Brahmer, MD, from the Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore, US, presented key patient-related outcomes from KEYNOTE-024,…
-
NCI Corner – Interview with Shakun Malik, MD
Posted: February 2017 By Erik J. Maclaren, PhD 2017 Mesothelioma Clinical Trials Planning Meeting Malignant mesothelioma is one of the most difficult cancers to control using existing therapies. Due to the rarity of this disease, randomized trials for potential new treatments are lacking. In order to facilitate clinical trials in patients with malignant mesothelioma, the…
-
Best of IASLC WCLC 2016
The Best of IASLC WCLC is an educational initiative of IASLC designed to engage researchers and practitioners unable to attend the IASLC 17th World Conference on Lung Cancer. The program condenses the timeliest scientific and educational topics from multiple disciplines into a 1- or 2-day event (typically 6-8 hours of educational sessions per day). Presented…
-
Highlights from IASLC WCLC 2016
Posted: February 2017 By Lori Alexander, MTPW, ELS, MWC With more than 2,500 presentations at the IASLC World Conference on Lung Cancer (WCLC) 2016, in Vienna, Austria, it is impossible to report on all new developments in the prevention, diagnosis, and treatment of lung cancer. However, some themes did emerge, most notably tobacco control and…
-
Nothing Plain about Plain Packaging
Posted: February 2017 By Kenneth Michael Cummings, PhD, MPH Cigarette packaging designs with different logos, imagery, size configurations and color schemes have been an important marketing tool used by manufacturers to attract different groups to try specific cigarette brands and sub-brands. For example, slim and elegant packaging with feminine imagery is used to attract young…